Bluebird Bio Issues LYFGENIA Boxed Warning: Hematologic Malignancy Has Occurred In Patients Treated With The Drug; Patients Should Monitor For Evidence Of Malignancy Through Complete Blood Counts At Least Every 6 Months, Through Integration Site Analysis
Bluebird Bio Issues LYFGENIA Boxed Warning: Hematologic Malignancy Has Occurred In Patients Treated With The Drug; Patients Should Monitor For Evidence Of Malignancy Through Complete Blood Counts At Least Every 6 Months, Through Integration Site Analysis
Bluebird Bio 發佈了 LYFGENIA 盒裝警告：接受該藥物治療的患者中出現了血液學惡性腫瘤；患者應通過整合位點分析，至少每 6 個月通過全血細胞計數監測惡性證據
Bluebird Bio Issues LYFGENIA Boxed Warning: Hematologic Malignancy Has Occurred In Patients Treated With The Drug; Patients Should Monitor For Evidence Of Malignancy Through Complete Blood Counts At Least Every 6 Months, Through Integration Site Analysis
Bluebird Bio 發佈了 LYFGENIA 盒裝警告：接受該藥物治療的患者中出現了血液學惡性腫瘤；患者應通過整合位點分析，至少每 6 個月通過全血細胞計數監測惡性證據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。